JMP reiterates market outperform for Oscient

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a market outperform rating with a $3 price target. Factive prescriptions for the week ended Nov. 18 were 5,527, representing 0.85% of weekly prescriptions for the quinolone class of antibiotics, compared with 5,555 prescriptions the previous week. Testosterone gel Testim prescriptions were 4,839 for the week ended Nov. 18 compared with 4,898 prescriptions the previous week. Shares of the Waltham, Mass., drug development company were up 4 cents, or 2.06%, at $1.98 on volume of 258,233 shares versus the three-month running average of 665,862 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.